Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast05: T-DXd vs T-DM1 in High-Risk HER2-Positive Primary Breast Cancer
NCT04622319Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Invasive Disease-free Survival at 57 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04622319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622319.